126 related articles for article (PubMed ID: 10365674)
41. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
42. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose.
Joensuu H; Ahonen A
J Nucl Med; 1987 May; 28(5):910-4. PubMed ID: 3572549
[TBL] [Abstract][Full Text] [Related]
43. [Clinical value of 99mTc-MIBI imaging, 131I whole body scan and HTG determination for the follow-up of patients with differentiated thyroid carcinoma after 131I therapy].
Yu N; Guan C; Liu Y; Yang X
Hua Xi Yi Ke Da Xue Xue Bao; 1999 Dec; 30(4):437-9. PubMed ID: 11387963
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
Ringel MD; Ladenson PW
J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
[TBL] [Abstract][Full Text] [Related]
45. 201ti scintigraphy in postoperative detection of thyroid cancer: a comparative study with 131i.
Tonami N; Hisada K
Radiology; 1980 Aug; 136(2):461-4. PubMed ID: 7403524
[TBL] [Abstract][Full Text] [Related]
46. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
47. Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma.
Lorberboym M; Murthy S; Mechanick JI; Bergman D; Morris JC; Kim CK
J Nucl Med; 1996 Sep; 37(9):1487-91. PubMed ID: 8790199
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.
Miyamoto S; Kasagi K; Misaki T; Alam MS; Konishi J
J Nucl Med; 1997 Mar; 38(3):352-6. PubMed ID: 9074516
[TBL] [Abstract][Full Text] [Related]
49. [A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinomas].
Briele B; Hotze A; Kropp J; Bockisch A; Overbeck B; Grünwald F; Kaiser W; Biersack HJ
Nuklearmedizin; 1991 Aug; 30(4):115-24. PubMed ID: 1788076
[TBL] [Abstract][Full Text] [Related]
50. [Thyroglobulin as a tumor marker and thallium scintigraphy for the course control of differentiated thyroid cancer].
Müller-Brand J; Fridrich R; Spicher E; Staub JJ
Schweiz Med Wochenschr; 1983 Mar; 113(9):325-7. PubMed ID: 6844904
[TBL] [Abstract][Full Text] [Related]
51. [Quantitated thyroid scan (123I) of the thyroid nodule: a new molecular imaging].
Clerc J
J Radiol; 2009 Mar; 90(3 Pt 2):371-91. PubMed ID: 19421128
[TBL] [Abstract][Full Text] [Related]
52. Reinforcing the Ability of 99mTcO4 Scintigraphy for Identifying Differentiated Thyroid Cancer by TSH Stimulation.
Ahn BC
Clin Nucl Med; 2016 Sep; 41(9):e412-3. PubMed ID: 27405037
[TBL] [Abstract][Full Text] [Related]
53. Comparison of whole body scintigraphy with Tc-99m-methoxyisobutylisonitrile and iodine-131 NA in patients with differentiated thyroid cancer.
Al Saleh K; Safwat R; Al-Shammeri I; Abdul Naseer M; Hooda H; Al-Mohannadi S
Gulf J Oncolog; 2007 Jan; 1(1):29-33. PubMed ID: 20084711
[TBL] [Abstract][Full Text] [Related]
54. Imaging modalities in the follow-up of non-iodine avid thyroid carcinoma.
Mallin WH; Elgazzar AH; Maxon HR
Am J Otolaryngol; 1994; 15(6):417-22. PubMed ID: 7872477
[TBL] [Abstract][Full Text] [Related]
55. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone.
Hung GU; Ho M; Kao CH
Clin Nucl Med; 2009 May; 34(5):316-7. PubMed ID: 19387216
[No Abstract] [Full Text] [Related]
56. F-18 FDG uptake by recurrent Hürthle cell carcinoma of the thyroid using high-energy planar scintigraphy.
Blount CL; Dworkin HJ
Clin Nucl Med; 1996 Nov; 21(11):831-3. PubMed ID: 8922841
[TBL] [Abstract][Full Text] [Related]
57. [Roles of single photo emission computed tomography-CT in detecting residual tumor from patients with thyroid carcinoma].
Song M; Chen FJ; Fan W; Wei MW; Chen WK
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Mar; 42(3):211-6. PubMed ID: 17633282
[TBL] [Abstract][Full Text] [Related]
58. Selection of the optimal scanning agent for thyroid cancer.
Sisson JC
Thyroid; 1997 Apr; 7(2):295-302. PubMed ID: 9133704
[TBL] [Abstract][Full Text] [Related]
59. Challenges and strategies on radioiodine treatment for differentiated thyroid carcinoma.
Cheng L; Liu M; Ruan M; Chen L
Hell J Nucl Med; 2016; 19(1):23-32. PubMed ID: 26929937
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation.
Juweid M; O'Dorisio T; Milhem M
N Engl J Med; 2008 Sep; 359(12):1295-7. PubMed ID: 18799567
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
